This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 1, 2015
- BioPharm International-06-01-2015
- Volume 28
- Issue 6
Biocompatible pH Sensor Ensures Reliability
Hamilton’s EasyFerm Bio biocompatible pH sensor is designed for CIP, sterilization up to 140 °C, autoclavable temperature, and a pressure range up to 6bar.
Advertisement
Hamilton’s EasyFerm Bio biocompatible pH sensor is designed for cleaning in place (CIP), sterilization up to 140 °C, autoclavable temperature up to 130 °C, has a pressure range up to 6bar, a 120 mm a-length, and a 12 mm diameter.
The sensor is made with pH glass and a reference HP-Coatramic diaphragm, and can withstand frequent autoclaving, steam sterilization, and CIP. The sensor has a measuring range from pH 0 to 14 with a NTC 22 kOhm temperature sensor.
Hamilton
Articles in this issue
over 11 years ago
Host-Cell Protein Measurement and Controlover 11 years ago
Advanced Technologies Facilitate Scale-up and Technology Transferover 11 years ago
What’s In a Name? For Biosimilars, A Lotover 11 years ago
Sterile Filtration Techniques for Optimal Microbial Retentionover 11 years ago
Quality Systems Key to Lifecycle Drug Managementover 11 years ago
Another In-House Operation Gets Outsourcedover 11 years ago
Automated Handwashing System Increases Efficiencyover 11 years ago
Your Insight Can Create Industry Benefitsover 11 years ago
BioPharm International, June 2015 Issue (PDF)over 11 years ago
Market Access Outlook for AustraliaAdvertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5